In vitro evaluation of novel consensus-sequence-generated Brevinin-2 antimicrobial peptides.

A novel consensus-sequence-designed Brevinin-2 peptide, G37, inhibits carbapenemase-resistant Escherichia coli at 16 µM within 150 minutes, showing broad-spectrum activity.

• Why it matters: Antibiotic-resistant bacteria pose a significant global health threat, and current therapeutics are increasingly ineffective, highlighting the need for alternative antimicrobial strategies.
• What they did: Researchers synthesized four peptides (G30, G33, S33, G37) based on a consensus-sequence approach, purified them with RP-FPLC, and tested their antibacterial activity and toxicity against MDR bacteria, including carbapenemase-resistant strains.
• The result: G37 demonstrated rapid bactericidal activity, fully killing targeted bacteria within 150 minutes, despite moderate hemolytic toxicity, suggesting its potential as a scalable candidate for combating MDR pathogens.